Graphite Bio, Inc.

NASDAQ:GRPH

3.18 (USD) • At close March 21, 2024
Bedrijfsnaam Graphite Bio, Inc.
Symbool GRPH
Munteenheid USD
Prijs 3.18
Beurswaarde 185,193,342
Dividendpercentage 64.78%
52-weken bereik 3.05 - 29.82
Industrie Biotechnology
Sector Healthcare
CEO Ms. Kimberlee Cobleigh Drapkin CPA, CPA
Website https://www.graphitebio.com

An error occurred while fetching data.

Over Graphite Bio, Inc.

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for

Vergelijkbare Aandelen

Pieris Pharmaceuticals, Inc. logo

Pieris Pharmaceuticals, Inc.

PIRS

17.3 USD

Genenta Science S.p.A. logo

Genenta Science S.p.A.

GNTA

5.45 USD

Apyx Medical Corporation logo

Apyx Medical Corporation

APYX

1.19 USD

ImmunoPrecise Antibodies Ltd. logo

ImmunoPrecise Antibodies Ltd.

IPA

0.418 USD

ORIC Pharmaceuticals, Inc. logo

ORIC Pharmaceuticals, Inc.

ORIC

9.41 USD

Gritstone bio, Inc. logo

Gritstone bio, Inc.

GRTS

0.032 USD

CorMedix Inc. logo

CorMedix Inc.

CRMD

9.99 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)